Special report: intensity-modulated radiation therapy for cancer of the breast or lung
BlueCross BlueShield Association
Record ID 32006000037
English
Authors' objectives:
This special report seeks evidence from published studies to determine whether intensity-modulate radiation therapy (IMRT) is superior to 3-dimensional conformal radiation therapy (3D-CRT) for improving health outcomes of patients with either breast or lung cancer.
Authors' results and conclusions:
No studies were identified (randomized or nonrandomized; prospective or retrospective) that directly compared health outcomes of IMRT with health outcomes of 3D-CRT (using concurrent or historical controls). Follow-up was short (<1 year) in the 2 available single-arm (non-comparative) studies on IMRT for breast cancer. Acute skin toxicity and cosmesis were the only outcomes reported. The only available single-arm study on lung cancer, a dose-escalation trial, closed for excessive toxicity after 5 patients received 84 Gy.
Authors' recommendations:
Available data are insufficient to determine whether IMRT is superior to 3D-CRT for improving health outcomes of patients with breast or lung cancer.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/contact-tec.html
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Radiotherapy, Intensity-Modulated
- Breast Neoplasms
- Lung Neoplasms
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.